Manufacturing, Packaging & Detailing Market Research Reports & Industry Analysis
Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA. The cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities.
Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.
The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.
- Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
- Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
- Use of checkweighers and sorters
- Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
- Use of quality control labeling systems
It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.
Manufacturing, Packaging & Detailing Industry Research & Market Reports
-
Angina Pectoris Drugs
... at a CAGR of 4.5% over the analysis period 2024-2030. Beta Blockers, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$9.6 Billion by the end of ... Read More
-
Bulk Paclitaxel
... CAGR of 8.5% over the analysis period 2024-2030. Semi-Synthetic Paclitaxel API, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$139.1 Million by the end of the ... Read More
-
Superdisintegrants
... 5.4% over the analysis period 2024-2030. Synthetic Superdisintegrants, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$262.2 Million by the end of the analysis period. Growth ... Read More
-
Triacetin
... 4.3% over the analysis period 2024-2030. Plasticizer, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$193.2 Million by the end of the analysis period. Growth in ... Read More
-
Sterility Testing
... CAGR of 10.9% over the analysis period 2024-2030. Kits & Reagents, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$184.9 Million by the end of the ... Read More
-
Sterols
... 5.8% over the analysis period 2024-2030. Vegetable oil, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$937.0 Million by the end of the analysis period. Growth ... Read More
-
Bio/Pharmaceutical Outsourcing Report, March 2025
... outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing ... Read More
-
2025 Global Generic Active Pharmaceutical Ingredients Market Industry (2031 Outlook)
... data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for 46 countries. The report also features written analysis on market definitions, market segments, market trends, ... Read More
-
Myeloproliferative Disorders Drugs
... at a CAGR of 4.3% over the analysis period 2024-2030. Ph+ Chronic myelogenous leukemia (CML), one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$9.2 Billion by ... Read More
-
Personalized Nutrition
... CAGR of 13.5% over the analysis period 2024-2030. Active Measurement, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$27.5 Billion by the end of the analysis ... Read More
-
Pharmaceutical Processing Seals
... at a CAGR of 8.2% over the analysis period 2024-2030. O-Rings, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$2.8 Billion by the end of the ... Read More
-
Pharmaceutical Glass Tubing
... at a CAGR of 5.7% over the analysis period 2024-2030. Glass Tubing for Syringes, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$8.1 Billion by the ... Read More
-
Anti-Allergy Drugs
... CAGR of 7.1% over the analysis period 2024-2030. Pharmacies, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$35.4 Billion by the end of the analysis period. ... Read More
-
Alzheimer’s Disease Drugs
... at a CAGR of 5.6% over the analysis period 2024-2030. Donepezil, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$5.2 Billion by the end of the ... Read More
-
Analgesics
... 5.3% over the analysis period 2024-2030. Prescription, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$43.8 Billion by the end of the analysis period. Growth in ... Read More
-
Coenzyme Q10
... CAGR of 4.5% over the analysis period 2024-2030. Dietary Supplements, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$609.1 Million by the end of the analysis ... Read More
-
Glucosamine
... 6.9% over the analysis period 2024-2030. Nutritional Supplements, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth ... Read More
-
Efficacy Testing
... CAGR of 10.4% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$713.2 Million by the end of the analysis period. ... Read More
-
Anticholinergic Drugs
... CAGR of 5.0% over the analysis period 2024-2030. Synthetic Compounds, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$6.6 Billion by the end of the analysis ... Read More
-
Calcium Channel Blockers
... at a CAGR of 6.1% over the analysis period 2024-2030. Dihydropyridine, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$17.1 Billion by the end of the ... Read More
-
Sodium Alginate
... CAGR of 5.0% over the analysis period 2024-2030. Stabilizers, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$137.4 Million by the end of the analysis period. ... Read More
-
Myelodysplastic Syndrome (MDS) Drugs
... 2030, growing at a CAGR of 9.3% over the analysis period 2024-2030. Immunomodulatory Drugs, one of the segments analyzed in the report, is expected to record a 9.5% CAGR and reach US$2.7 Billion by the ... Read More
-
Antiemetic Drugs
... CAGR of 5.4% over the analysis period 2024-2030. Chemotherapy Application, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$3.2 Billion by the end of the analysis ... Read More
-
Benign Prostatic Hyperplasia (BPH) Drugs
... Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Alpha-Blockers, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$7.4 Billion by ... Read More
-
Contract Packaging
... CAGR of 8.7% over the analysis period 2024-2030. Food & Beverage End-Use, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$55.4 Billion by the end of ... Read More
Research Assistance
